Development and characterization of dried blood spot materials for the measurement of immunoreactive trypsinogen

Journal of Medical Screening

Volumn 13, Issue 2, 2006, Pages 79-84

  Li, Lixia ^a   Zhou, Yingtao ^a   Bell, Carol J ^a   Earley, Marie C ^a   Hannon, W Harry ^a   Mei, Joanne V ^a,b  

^a NATIONAL CENTER FOR ENVIRONMENTAL HEALTH   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CHARCOAL; PROTEINASE INHIBITOR; TRYPSINOGEN;

ANALYSIS; ARTICLE; BABY; BLOOD; CYSTIC FIBROSIS; ERYTHROCYTE; EVALUATION; FILTER; HEALTH PROGRAM; HEMOLYSIS; HUMAN; IMMUNOREACTIVITY; LABORATORY DIAGNOSIS; LABORATORY TEST; MEASUREMENT; MOLECULAR STABILITY; PHYSIOLOGY; PILOT STUDY; PROTEIN ANALYSIS; SCREENING; SEPARATION TECHNIQUE; SERUM; STORAGE TEMPERATURE; UNITED STATES;

CHARCOAL; CYSTIC FIBROSIS; HUMANS; INFANT, NEWBORN; MASS SCREENING; MUTATION; NEONATAL SCREENING; PILOT PROJECTS; PROTEASE INHIBITORS; QUALITY CONTROL; SPECIMEN HANDLING; TEMPERATURE; TRYPSINOGEN; UNITED STATES;

EID: 33745287756     PISSN: 09691413     EISSN: 09691413     Source Type: Journal    
DOI: 10.1258/096914106777589623     Document Type: Article

References (26)

1. Welsh MJ, Tsui LC, Boat TF, et al. Cystic fibrosis. In: Scriver CF, Beaudet AL, Sly WS, et al., eds. The Metabolic and Molecular Bases of Inherited Disease. 7th edn. New York: McGraw-Hill, 1995;3799-876
2. Farrell PM, Mischler EH. Newborn screening for cystic fibrosis. Adv Pediatr 1992;39:31-64
3. Kosorok MR, Wei W, Farrel PM. The incidence of cystic fibrosis. Stat Med 1996;15:449-62
4. National Newborn Screening and Genetics Resource Center. National newborn screening report - 2000 Final report: February 2003. http://genes-r-us.uthscsa. edu/resources/newborn/00/ch10_complete.pdf(last accessed 10/06/05)
5. Crossley JR, Elliott RB, Smith PA. Dried-blood spot screening for cystic fibrosis in the newborn. Lancet 1979;1:472-4
6. Marx JL. The cystic fibrosis gene is found. Science 1989;245:923-5
7. Assael BM, Castellani C, Ocampo MB, et al. Epidemiology and survival analysis of cystic fibrosis in an area of intense neonatal screening over 30 years. Am J Epidemiol 2002;156:397-401
8. Wilcken B, Wiley V. Newborn screening methods for cystic fibrosis. Paediatr Respir Rev 2003;4:272-7
9. Centers for Disease Control and Prevention. Newborn screening for cystic fibrosis: a paradigm for public health genetics policy development; proceedings of a 1997 workshop. Morb Monthly Wkly Rep 1997;46:1-22
10. Wilcken B, Chalmers G. Reduced morbidity in patients with cystic fibrosis detected by neonatal screening. Lancet 1985;2:1319-21
11. Dankert-Roelse JE, Meerman GJ, Martin A, et al. Survival and clinical outcome in patients with cystic fibrosis, with or without neonatal screening. J Pediatr 1989;114:362-7
12. Waters DL, Wilcken B, Irwig L, et al. Clinical outcomes of newborn screening for cystic fibrosis. Arch Dis Child Fetal Neonatal Ed 1999;80:F1-7
13. Farrell PM. Improving the health of patients with cystic fibrosis through newborn screening. Wisconsin Cystic Fibrosis Neonatal Screening Study Group. Adv Pediatr 2000;47:79-15
14. Farrell PM, Lai HCJ, Li ZH, et al. Evidence on improved outcomes with early diagnosis of cystic fibrosis through neonatal screening: Enough is enough!. J Pediatr 2005;147:S30-6
15. Lai HCJ, Cheng Y, Farrell PM. The survival advantage of patients with cystic fibrosis diagnosed through neonatal screening: Evidence from the United States Cystic Fibrosis Foundation registry data. 2005;147:S57-63
16. Centers for Disease Control and Prevention. Newborn screening for cystic fibrosis: evaluation of benefits and risks and recommendations for state newborn screening programs. Morb Monthly Wkly Rep 2004;53:1-37
17. Narzi L, Lucarelli M, Lelli A, et al. Comparison of two different protocols of neonatal screening for cystic fibrosis. Clin Genet 2002;62:245-9
18. Sontag MK, Hammond KB, Zielenski J, et al. Two-tiered immunoreactive trypsinogen-based newborn screening for cystic fibrosis in Colorado: screening efficacy and diagnostic outcomes. J Pediatr 2005;147:S83-8
19. Rock MJ, Hoffman G, Laessig RH, Kopish GJ, Litsheim TJ. Newborn screening for cystic fibrosis in Wisconsin: nine-year experience with routine trypsin/DNA testing. J Pediatr 2005;147:S73-7
20. Jameson G, Elmore D. Affinity chromatography of bovine trypsin. A rapid separation of bovine (alpha) and (beta) trypsin. J Biochem 1974;141:555-65
21. Webster D, Hannon H, Ranieri E, Francis I, et al. Quality assurance in CF screening. In: Travert G, Wursteisen B, eds. Neonatal Screening for Cystic Fibrosis. Proceedings of the International Conference; 1998. 10-11 Caen, France. Caen: Université de Caen, 1999;71-6
22. Slazyk WE, Hannon WH. Quality assurance in the newborn screening laboratory. In: Therrell Jr BL, ed. Laboratory Methods for Neonatal Screening. Washington, DC: American Public Health Association, 1993;23-41
23. Heeley ME, Travert G, Ferré C, et al. The International Quality Assurance Program (IRTIQAS) for the assay of immunoreactive trypsinogen in dried blood spots. Pediatr Pulmonol Suppl 1991;7:72-5
24. Abbott F, Gomez JE, Birnbaum ER, et al. The location of the calcium ion binding site in bovine alpha-trypsin and beta-trypsin using lanthanide ion probes. Biochemistry 1975;14:4935-43
25. Nureddin A, Inagami T. Chemical modification of amino groups and guanidine groups of trypsin. Preparation of stable and soluble derivatives. Biochem J 1975;147:71-81
26. Zhou Y, Earley MC, Li L, et al. Use of fluorescence polarization to detect the cystic fibrosis F508 mutation in dried blood spots. In: 2004 Newborn Screening and Genetic Testing Symposium; 2004 May 3-6; Atlanta, GA. Washington, DC: Association of Public Health Laboratories, 2004;156-7